Heretofore all attempts to demonstrate protective antibody in antitularense serums have failed whenever animals were challenged with a strain of high virulence. Previous test animals have been the mouse, guinea pig, hamster, and rabbit. Sources of immune or hyperimmune serums were goats, horses, sheep, rabbits, and man: Our considerable unpublished experience with these animals and serums is in good agreement with the reports of Francis and Felton (1) and Bell and Kahn (2). If injected with serum before challenge these animals will usually exhibit significant prolongations of the survival time beyond that of control animals, but no actual survivals against as little as 1 to 10 M.L.D. of a virulent challenge strain.
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The inability to demonstrate serum protection in these highly susceptible animals has contributed to a widespread but unfounded belief that immune and hyperimmune serums are ineffective therapeutic agents in human tularemia. Although reports by Foshay (3, 4) on the results of serum therapy in individual patients, as well as analyses of accumulated data derived from the independent observations of more than 600 clinical observers, have continued to demonstrate significant reductions in mortality and highly significant reductions in morbidity in comparison with comparable data from untreated patients, universal acceptance of the value of serum therapy has been impeded by a lack of suitable means to demonstrate protective antibody and to establish quantitative criteria for potency. The work here reported was undertaken to supply these deficiencies.
The inability of the highly susceptible mouse, guinea pig, hamster, and rabbit to react with any useful degree of resistance before death occurs. following infection with a single virulent unit of Bacterium tularense makes these animals unsuitable test hosts for serum protection experiments.
The reasons for this inability, obviously inoperative for many other infectious agents under similar conditions of testing, are unknown at present. The reactions of these animals to invasion are quite unlike that of man, for whom there is ample evidence that the great majority rapidly develop a high degree of resistance, resulting-in a disease that is characterized clinically by a low mortality and, pathologically, by tissue reactions that soon exhibit subacuteness and chronicity.
During the course of the initial investigations on this disease, McCoy (5) Serum protection tests. Serum protection tests were performed in the following manner. Rats were inoculated in groups of 30 to 32, half of each group receiving one of the potent serums and the other half receiving either the corresponding normal serum or the aged immune goat serum. Each rat was injected intraperitoneally with 2 ml. of undiluted serum and immediately thereafter with the 1-ml. challenge dose, subcutaneously, into the abdominal wall near the groin. The 2-ml. serum dosage was selected with reference to the agglutinin titer curves of pooled serums from normal rats after intraperitoneal injections of an immune goat serum with a titer of 1: 5,120. Rats that received 2 ml. of serum had titers of 1: 1,280 at 24 hours, and 1: 160 at 48 hours. Rats that received 1 ml. of serum had titers of 1: 160 at 24 hours, and zero in 1: 10 dilution at 48 hours. Deaths were recorded daily for 21 days before release. The infecting strain was recovered from a rat dying on the second or third day from each group, and was used to infect each succeeding group.
Determination of persistence of infection in the spleens of recovered rats. After release all recovered animals were held for sacrifice at weekly intervals from 3 weeks to 3 months after challenge and were tested for residual splenic infection by cultures and by intraperitoneal inoculations into mice of suspensions of ground spleens. Comparative mortalities and cumulative LD6o titers after subcutaneous and intraperitoneal inoculation. Dosage was 1 ml. for rats, 0.5 ml. for mice. Serum protection of rats in relation to precipitable antibody content. The results of serum protection experiments are given in Table II . In- 
DISCUSSION
The decisive results of the serum-protection experiments demonstrated conclusively that protective antibody was present in antitularense serums. The observed differences in mortality between rats that received immune serums and those that received normal serums are significant by inspection. The degrees of significance of the mortality rates from groups A, B, C and D, in comparison with the rate obtained after pretreatment with normal horse serum, are extremely high, all values of p being so small that they are unimaginable figures. Since the virulence titrations in rats having a slightly higher maximal weight limit showed that stability was not reliably secured with fewer than 90 rats, we attach less significance to the observed differences in mortality among groups A, B, C and D. Inspection of the paired mortality ratios for groups B, C and D reveals that variable individual resistance among rats in the narrower weight range was still operative. Hence, it is unlikely that significant differences in potency between these serums could be determined without using a much larger number of rats for each serum. Analysis of the rates for groups A, B and C, in comparison with the rate from group D, showed that no difference was significant, though that between groups D and A barely escaped statistical significance.
The protection test employed is satisfactory to determine the presence or absence of protective antibody. In the above tests it actually gave good agreement between rat survival and antibody content for all serums, and it is perhaps possible that repetition might continue to reveal proportional differences in protective antibody in serums of graded potency in agreement with their respective precipitable antibody contents, but, unless larger numbers of animals were used for each serum, conclusions about the relative potencies are not really justified. It is apparent from the mortality of rats in group D that a very small amount of antibody is sufficient to tip the balance heavily in favor of survival, even against a large challenge dose of a strain of maximal virulence.
The variable resistance of rats to subcutaneous challenge would have necessitated the use of so many animals per serum dilution that determinations of the ED50 doses of serums were impractical. The possibility of securing more significant degrees of relative serum protection, with the same or a smaller number of animals, by means of a suitable intraperitoneal challenge dose has not been explored.
Although the protection test described provides a method for the demonstration of protective antibody in antitularense serums it does not in its present form furnish an accurate basis for the establishment of quantitative criteria for potency. Further study of the precipitable antibody content in relation to protective capacity may eventually provide a serologic method to quantitate the potency of serums, thus obviating the use of test animals. Until a satisfactory method is devised temporary safeguards might be adopted. For example, a provisional standard might require a minimum of 1 mgm. equivalent of antibody per ml. of serum or perhaps a survival rate of 75 per cent among rats selected and challenged in accordance with the above specifications.
SUMMARY
Protective antibody was demonstrated in antitularense serums against subcutaneous challenge with an average of 25,000 LDio doses of a strain of Bacterium tularense of maximal virulence, using white rats of 85 to 110 grams as the test animals. Good correlation was observed between protective antibody and precipitable antibody content, but not between antibody content and agglutinin titers.
